120 related articles for article (PubMed ID: 29299751)
1. Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.
Honecker F; Wedding U; Kallischnigg G; Schroeder A; Klier J; Frangenheim T; Weißbach L
J Cancer Res Clin Oncol; 2018 Mar; 144(3):571-577. PubMed ID: 29299751
[TBL] [Abstract][Full Text] [Related]
2. [Prediction of unplanned discontinuation of treatment in patients with castration-resistant prostate cancer-results from the IBuTu study].
Honecker F; Wedding U; Kallischnigg G; Schroeder A; Klier J; Frangenheim T; Weißbach L
Urologe A; 2018 Aug; 57(8):909-918. PubMed ID: 29978302
[No Abstract] [Full Text] [Related]
3. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
Italiano A; Ortholan C; Oudard S; Pouessel D; Gravis G; Beuzeboc P; Bompas E; Fléchon A; Joly F; Ferrero JM; Fizazi K
Eur Urol; 2009 Jun; 55(6):1368-75. PubMed ID: 18706755
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
5. The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO).
Lund CM; Vistisen KK; Dehlendorff C; Rønholt F; Johansen JS; Nielsen DL
BMC Cancer; 2017 Jun; 17(1):448. PubMed ID: 28659138
[TBL] [Abstract][Full Text] [Related]
6. Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
Gerritse FL; Meulenbeld HJ; Roodhart JM; van der Velden AM; Blaisse RJ; Smilde TJ; Erjavec Z; de Wit R; Los M;
Eur J Cancer; 2013 Oct; 49(15):3176-83. PubMed ID: 23849828
[TBL] [Abstract][Full Text] [Related]
7. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
8. Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results.
Della Pepa C; Cavaliere C; Rossetti S; Di Napoli M; Cecere SC; Crispo A; De Sangro C; Rossi E; Turitto D; Germano D; Iovane G; Berretta M; D'Aniello C; Pisconti S; Maiorino L; Daniele B; Gridelli C; Pignata S; Facchini G
Anticancer Drugs; 2017 Jan; 28(1):104-109. PubMed ID: 27579728
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.
Sternberg CN; Baskin-Bey ES; Watson M; Worsfold A; Rider A; Tombal B
BMC Urol; 2013 Nov; 13():58. PubMed ID: 24206580
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
11. A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.
Manokumar T; Aziz S; Breunis H; Rizvi SF; Joshua AM; Tannock IF; Alibhai SM
J Geriatr Oncol; 2016 Mar; 7(2):81-9. PubMed ID: 26853769
[TBL] [Abstract][Full Text] [Related]
12. Predictors of 1-Year Mortality in a Prospective Cohort of Elderly Patients With Cancer.
Ferrat E; Paillaud E; Laurent M; Le Thuaut A; Caillet P; Tournigand C; Lagrange JL; Canouï-Poitrine F; Bastuji-Garin S;
J Gerontol A Biol Sci Med Sci; 2015 Sep; 70(9):1148-55. PubMed ID: 25834194
[TBL] [Abstract][Full Text] [Related]
13. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
14. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.
Emmenegger U; Booth CM; Berry S; Sridhar SS; Winquist E; Bandali N; Chow A; Lee C; Xu P; Man S; Kerbel RS; Ko YJ
Oncologist; 2015 Dec; 20(12):1351-2. PubMed ID: 26542984
[TBL] [Abstract][Full Text] [Related]
15. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
Aparicio T; Jouve JL; Teillet L; Gargot D; Subtil F; Le Brun-Ly V; Cretin J; Locher C; Bouché O; Breysacher G; Charneau J; Seitz JF; Gasmi M; Stefani L; Ramdani M; Lecomte T; Mitry E
J Clin Oncol; 2013 Apr; 31(11):1464-70. PubMed ID: 23460711
[TBL] [Abstract][Full Text] [Related]
16. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
[TBL] [Abstract][Full Text] [Related]
17. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
[TBL] [Abstract][Full Text] [Related]
18. Population-based study on use of chemotherapy in men with castration resistant prostate cancer.
Lissbrant IF; Garmo H; Widmark A; Stattin P
Acta Oncol; 2013 Nov; 52(8):1593-601. PubMed ID: 23427879
[TBL] [Abstract][Full Text] [Related]
19. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
